Medicines Co. Gains Kengreal Approval; Can It Alter Clinical Practice Too?
This article was originally published in The Pink Sheet Daily
Antiplatelet's indication is narrow, but TMC hopes to leverage cultural changes in 'door-to-procedure' times.
You may also be interested in...
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.
The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.
Pink Sheet reporters and editor discuss the new monkeypox vaccine EUA, the potential impact of drug pricing legislation, and how things may have been different if the FDA already had a desired technology upgrade.